Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
March 4, 2009
Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design
E S Perloff, A K Mason, S S Dehal, et al.
Journal of Clinical Nursing
|
January 4, 2022
Development and validation of the patient centeredness index for primary care
Gail L Rose, Levi N Bonnell, Jennifer B O'Rourke-Lavoie, et al.
Cell
|
September 20, 2024
Nothing about us without us: Sharing results with communities that provide genomic data
Sarah LeBaron von Baeyer, Rebecca M Crocker, Rindra Rakotoarivony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Biorxiv : the Preprint Server for Biology
|
June 3, 2026
Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy
Kylie E Preihs, Kubra Karagoz, Claire R Shuey, et al.
Cancer Research
|
April 9, 2020
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment
Jonathan M Harnoss, Adrien Le Thomas, Mike Reichelt, et al.
Cancer Research
|
November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Cancer Cell
|
October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
Gabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Molecular Cancer Therapeutics
|
December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer
Sunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Trials
|
March 11, 2021
Integrating Behavioral Health and Primary Care (IBH-PC) to improve patient-centered outcomes in adults with multiple chronic medical and behavioral health conditions: study protocol for a pragmatic cluster-randomized control trial
Abigail M Crocker, Rodger Kessler, Constance van Eeghen, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
March 4, 2009
Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design
E S Perloff, A K Mason, S S Dehal, et al.
Journal of Clinical Nursing
|
January 4, 2022
Development and validation of the patient centeredness index for primary care
Gail L Rose, Levi N Bonnell, Jennifer B O'Rourke-Lavoie, et al.
Cell
|
September 20, 2024
Nothing about us without us: Sharing results with communities that provide genomic data
Sarah LeBaron von Baeyer, Rebecca M Crocker, Rindra Rakotoarivony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Biorxiv : the Preprint Server for Biology
|
June 3, 2026
Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy
Kylie E Preihs, Kubra Karagoz, Claire R Shuey, et al.
Cancer Research
|
April 9, 2020
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment
Jonathan M Harnoss, Adrien Le Thomas, Mike Reichelt, et al.
Cancer Research
|
November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Cancer Cell
|
October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
Gabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Molecular Cancer Therapeutics
|
December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer
Sunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Trials
|
March 11, 2021
Integrating Behavioral Health and Primary Care (IBH-PC) to improve patient-centered outcomes in adults with multiple chronic medical and behavioral health conditions: study protocol for a pragmatic cluster-randomized control trial
Abigail M Crocker, Rodger Kessler, Constance van Eeghen, et al.
Page
of 10